Adamsbrown Wealth Consultants’s VanEck Pharmaceutical ETF PPH Stock Holding History

Adamsbrown Wealth Consultants’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.9M	Buy	154,114 +5,303	+4%	+$549K	3.18%	11
2026 Q1	$15.5M	Buy	148,811 +5,766	+4%	+$614K	4.09%	7
2025 Q4	$14.8M	Buy	143,045 +6,146	+4%	+$598K	4.11%	7
2025 Q3	$12.4M	Sell	136,899 -59,077	-30%	-$5.17M	3.41%	10
2025 Q2	$17.2M	Buy	195,976 +21,074	+12%	+$1.83M	5%	8
2025 Q1	$15.9M	Buy	174,902 +25,271	+17%	+$2.28M	5.01%	7
2024 Q4	$12.9M	Buy	149,631 +75,659	+102%	+$6.84M	4.4%	9
2024 Q3	$7.03M	Buy	+73,972	New	+$7.03M	2.44%	12

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Adamsbrown Wealth Consultants's PPH Position: Q2 2026 in Review

Adamsbrown Wealth Consultants increased its VanEck Pharmaceutical ETF (PPH) stake by 3.6% in Q2 2026, buying an estimated $549K and bringing the position to 154,114 shares worth $16.9M. The position accounts for 3.18% of the portfolio, ranked #11.

Adamsbrown Wealth Consultants first reported a position in PPH in Q3 2024 and has held it in 8 quarters since. The position peaked at $17.2M in Q2 2025. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Adamsbrown Wealth Consultants held 154,114 shares of VanEck Pharmaceutical ETF worth $16.9M as of Q2 2026.
Adamsbrown Wealth Consultants bought 5,303 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $549K.
VanEck Pharmaceutical ETF made up 3.18% of Adamsbrown Wealth Consultants's portfolio in Q2 2026, its #11 holding.
Adamsbrown Wealth Consultants first reported a position in VanEck Pharmaceutical ETF in Q3 2024 and has held it in 8 quarters since.
Adamsbrown Wealth Consultants's VanEck Pharmaceutical ETF position peaked at $17.2M in Q2 2025.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Adamsbrown Wealth Consultants's 13F filing for Q2 2026, filed 9 Jul 2026.